ARCHIVES

Cancer Drugs Initiatives To Shorten approval Times, Ensure Post-Marketing Studies, FDA Official Says

This article is from The Cancer Letter archive.

Vol. 22 No. 17 | April 26, 1996

Download PDF Visit The Full Archive

Related Articles

In Brief: “The Journal” to Mae its Appearance In Jan., With Wittes As Editor; Manuscripts Solicited

October 16, 1987

In Brief: Ahoy! It’s “Admiral Rick”

April 2, 1999

President’s Cancer Panel annual report finds barriers in translational research stall progress.

July 8, 2005

“Bring Contracts Under Control, Save $100,00 A Year,” Samuels Tells NCI

November 2, 1979

FDA Committee Okays Leuprolide NDA, But Recommends Against Mitoxantrne, Epirubicin

April 5, 1985

Freement Lists Steps For Dealing With Disadvantaged

September 7, 1990